93 research outputs found
The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer
The insulin-like growth factor 2 (IGF2) mRNA binding protein IMP2 (IGF2BP2) is an
oncogenic protein known to be overexpressed in different tumor types. Pancreatic cancer is a very
lethal cancer that requires early diagnosis and new treatment options. The aim of our study was to
investigate the role of IMP2 in the initiation and progression of pancreatic ductal adenocarcinoma
(PDAC). IMP2 was significantly overexpressed in a human precursor (PanIN) lesions suggesting IMP2
as a marker for early stages of PDAC. In a PDAC cohort of matched normal and tumor samples IMP2
showed overexpression in tumor tissues compared with normal pancreatic tissue. Strict correlation
analysis (threshold R
2 > 0.75) revealed 22 genes highly positively and 9 genes highly negatively
correlating with IMP2. Besides genes involved in the inhibition of apoptosis (Bcl-XL), especially factors
involved in ubiquitination were strongly correlated with IMP2 expression: SMURF1 and FBXO45.
Moreover, protein kinase C (PKC) signaling pathway was distinctly affected: DXS1179E encoding
PKC iota, PKC substrate PLEK2, and inositol triphosphate receptor IP3R3 were positively correlated
with IMP2 expression. Besides tumor initiation, IMP2 also seemed to have an impact on tumor
progression. TGF-β treatment of Panc-1 pancreatic cancer cells to induce epithelial-mesenchymal
transition (EMT) was accompanied by increased IMP2 expression. EMT is important for cancer cells
to gain migratory and invasive potential, which is essential for metastasis. Concordantly, circulating
tumor cells showed higher IMP2 levels as compared with normal tissue from tumor origin and
with normal hematological cells. Accordingly, IMP2 protein levels correlated with poor survival.
In conclusion, as IMP2 seems to promote tumor progression of PDAC, it might be an interesting
diagnostic and prognostic marker as well as a novel target for the treatment of PDAC
Endotoxin Tolerance Acquisition and Altered Hepatic Fatty Acid Profile in Aged Mice
(1) Background: Aging is linked to an altered immune response and metabolism. Inflammatory conditions, such as sepsis, COVID-19, and steatohepatitis are more prevalent in the elderly
and steatosis is linked both to severe COVID-19 and sepsis. We hypothesized that aging is linked to a
loss of endotoxin tolerance, which normally protects the host from excessive inflammation, and that
this is accompanied by elevated levels of hepatic lipids. (2) Methods: An in vivo lipopolysaccharide
(LPS) tolerance model in young and old mice was used and the cytokine serum levels were measured
by ELISA. Cytokine and toll-like receptor gene expression was determined by qPCR in the lungs
and the liver; hepatic fatty acid composition was assessed by GC–MS. (3) Results: The old mice
showed a distinct potential for endotoxin tolerance as suggested by the serum cytokine levels and
gene expression in the lung tissue. Endotoxin tolerance was less pronounced in the livers of the aged
mice. However, the fatty acid composition strongly differed in the liver tissues of the young and
old mice with a distinct change in the ratio of C18 to C16 fatty acids. (4) Conclusions: Endotoxin
tolerance is maintained in advanced age, but changes in the metabolic tissue homeostasis may lead to
an altered immune response in old individuals
The Cytotoxicity and Insecticidal Activity of Extracts from Delphinium formosum Boiss. & Huet
Delphinium species are well-known toxic plants with diterpenoid alkaloid contents. There has been no previous investigation on the cytotoxicity of Delphinium formosum. The extracts of the different parts of D. formosum, an endemic species in Turkey, were investigated for their cytotoxic activity against the human liver carcinoma cell line (HepG2) and primary human umbilical vein endothelial cells (HUVEC). The cytotoxic effects of twelve extracts and subfractions were determined against HepG2 cells using the MTT assay. The only active extract was applied to the HUVEC as a model for healthy cells. Only one of the alkaloidcontaining extracts from the aerial parts was toxic (IC50=244,9 µg/mL against HepG2 and 144,4 µg/mL against HUVEC), while the root extracts were inactive. The results were improbable although it is predicted secondary metabolites, such as diterpene alkaloids (methyllycaconitine, browniine, lycoctonine, avardharidine, antranoyllycoctonine, delsemine A/B and lycoctonine). Based on previous studies in the literature, the cytotoxic plants were also expected to exhibit insecticidal activity. Therefore, the cytotoxic extract of D. formosum was examined for its adulticidal and larvicidal activity against the yellow fever, dengue fever and the Zika virus vector Aedes aegypti L
Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival
Background/Aims: Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related deaths worldwide, not least due to its high chemoresistance. The long non-coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1), localised in nuclear paraspeckles, has been shown to enhance chemoresistance in several cancer types. Since data on NEAT1 in HCC chemosensitivity are completely lacking and chemoresistance is linked to poor prognosis, we aimed to study NEAT1 expression in HCC chemoresistance and its link to HCC prognosis. Methods: NEAT1 expression was determined in either sensitive, or sorafenib, or doxorubicin resistant HepG2, PLC/PRF/5, and Huh7 cells by qPCR. Paraspeckles were detected by immunostaining of paraspeckle component 1 (PSPC1) in cell culture and in a cohort of HCC patients. PSPC1 expression was correlated with clinical data. The expression of transcript variants of NEAT1 and transcripts encoding the paraspeckle-associated proteins was analysed in the TCGA liver cancer data set. Results: NEAT1 was overexpressed in all three sorafenib and doxorubicin resistant cell lines. Paraspeckles were present in all chemoresistant cells, whereas no signal was detected in the sensitive cells. Expression of NEAT1 transcripts as well as transcripts encoding PSPC1, NONO, and RBM14 was increased in tumour tissue. Expression of PSPC1, NONO, and RBM14 transcripts was significantly associated with poor survival, whereas NEAT1 expression was not. Immunohistochemical analysis revealed that nuclear and cytoplasmic PSPC1-positivity was significantly associated with shorter overall survival of HCC patients. Conclusion: Our data show an induction of NEAT1 in HCC chemoresistance and a high correlation of transcripts encoding paraspeckle-associated proteins with poor survival in HCC. Therefore, NEAT1, PSPC1, NONO, and RBM14 might be promising targets for novel HCC therapies, and the paraspeckle-associated proteins might be clinical markers and predictors for poor survival in HCC
Kupffer cells are protective in alcoholic steatosis
Massive accumulation of lipids is a characteristic of alcoholic liver disease. Excess of hepatic fat activates Kupffer cells (KCs), which affect disease progression. Yet, KCs contribute to the resolution and advancement of liver injury. Aim of the present study was to evaluate the effect of KC depletion on markers of liver injury and the hepatic lipidome in liver steatosis (Lieber-DeCarli diet, LDC, female mice, mixed C57BL/6J and DBA/2J background). LDC increased the number of dead hepatocytes without changing the mRNA levels of inflammatory cytokines in the liver. Animals fed LDC accumulated elevated levels of almost all lipid classes. KC ablation normalized phosphatidylcholine and phosphatidylinositol levels in LDC livers, but had no effect in the controls. A modest decline of trigylceride and diglyceride levels upon KC loss was observed in both groups. Serum aminotransferases and hepatic ceramide were elevated in all animals upon KC depletion, and in particular, cytotoxic very long-chain ceramides increased in the LDC livers. Meta-biclustering revealed that eight lipid species occurred in more than 40% of the biclusters, and four of them were very long-chain ceramides. KC loss was further associated with excess free cholesterol levels in LDC livers. Expression of inflammatory cytokines did, however, not increase in parallel. In summary, the current study described a function of KCs in hepatic ceramide and cholesterol metabolism in an animal model of LDC liver steatosis. High abundance of cytotoxic ceramides and free cholesterol predispose the liver to disease progression suggesting a protective role of KCs in alcoholic liver diseases
The mRNA-binding Protein TTP/ZFP36 in Hepatocarcinogenesis and Hepatocellular Carcinoma
Hepatic lipid deposition and inflammation represent risk factors for hepatocellular carcinoma (HCC). The mRNA-binding protein tristetraprolin (TTP, gene name ZFP36) has been suggested as a tumor suppressor in several malignancies, but it increases insulin resistance. The aim of this study was to elucidate the role of TTP in hepatocarcinogenesis and HCC progression. Employing liver-specific TTP-knockout (lsTtp-KO) mice in the diethylnitrosamine (DEN) hepatocarcinogenesis model, we observed a significantly reduced tumor burden compared to wild-type animals. Upon short-term DEN treatment, modelling early inflammatory processes in hepatocarcinogenesis, lsTtp-KO mice exhibited a reduced monocyte/macrophage ratio as compared to wild-type mice. While short-term DEN strongly induced an abundance of saturated and poly-unsaturated hepatic fatty acids, lsTtp-KO mice did not show these changes. These findings suggested anti-carcinogenic actions of TTP deletion due to effects on inflammation and metabolism. Interestingly, though, investigating effects of TTP on different hallmarks of cancer suggested tumor-suppressing actions: TTP inhibited proliferation, attenuated migration, and slightly increased chemosensitivity. In line with a tumor-suppressing activity, we observed a reduced expression of several oncogenes in TTP-overexpressing cells. Accordingly, ZFP36 expression was downregulated in tumor tissues in three large human data sets. Taken together, this study suggests that hepatocytic TTP promotes hepatocarcinogenesis, while it shows tumor-suppressive actions during hepatic tumor progression
IGF2 mRNA Binding Protein 2 Transgenic Mice Are More Prone to Develop a Ductular Reaction and to Progress Toward Cirrhosis
The insulin-like growth factor 2 (IGF2) mRNA binding proteins (IMPs/IGF2BPs) IMP1 and 3 are regarded as oncofetal proteins, whereas the hepatic IMP2 expression in adults is controversially discussed. The splice variant IMP2-2/p62 promotes steatohepatitis and hepatocellular carcinoma. Aim of this study was to clarify whether IMP2 is expressed in the adult liver and influences progression toward cirrhosis. IMP2 was expressed at higher levels in embryonic compared to adult tissues as quantified in embryonic, newborn, and adult C57BL/6J mouse livers and suggested by analysis of publicly available human data. In an IMP2-2 transgenic mouse model microarray and qPCR analyses revealed increased expression of liver progenitor cell (LPC) markers Bex1, Prom1, Spp1, and Cdh1 indicating a de-differentiated liver cell phenotype. Induction of these LPC markers was confirmed in human cirrhotic tissue datasets. The LPC marker SPP1 has been described to play a major role in fibrogenesis. Thus, DNA methylation was investigated in order to decipher the regulatory mechanism of Spp1 induction. In IMP2-2 transgenic mouse livers single CpG sites were differentially methylated, as quantified by amplicon sequencing, whereas human HCC samples of a human publicly available dataset showed promoter hypomethylation. In order to study the impact of IMP2 on fibrogenesis in the context of steatohepatitis wild-type or IMP2-2 transgenic mice were fed either a methionine-choline deficient (MCD) or a control diet for 2-12 weeks. MCD-fed IMP2-2 transgenic mice showed a higher incidence of ductular reaction (DR), accompanied by hepatic stellate cell activation, extracellular matrix (ECM) deposition, and induction of the LPC markers Spp1, Cdh1, and Afp suggesting the occurrence of de-differentiated cells in transgenic livers. In human cirrhotic samples IMP2 overexpression correlated with LPC marker and ECM component expression. Progression of liver disease was induced by combined MCD and diethylnitrosamine (DEN) treatment. Combined MCD-DEN treatment resulted in shorter survival of IMP2-2 transgenic compared to wild-type mice. Only IMP2-2 transgenic livers progressed to cirrhosis, which was accompanied by strong DR. In conclusion, IMP2 is an oncofetal protein in the liver that promotes DR characterized by de-differentiated cells toward steatohepatitis-associated cirrhosis development with poor survival
IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer
Engineered reporter phages for detection of Escherichia coli, Enterococcus, and Klebsiella in urine
The rapid detection and species-level differentiation of bacterial pathogens facilitates antibiotic stewardship and improves disease management. Here, we develop a rapid bacteriophage-based diagnostic assay to detect the most prevalent pathogens causing urinary tract infections: Escherichia coli, Enterococcus spp., and Klebsiella spp. For each uropathogen, two virulent phages were genetically engineered to express a nanoluciferase reporter gene upon host infection. Using 206 patient urine samples, reporter phage-induced bioluminescence was quantified to identify bacteriuria and the assay was benchmarked against conventional urinalysis. Overall, E. coli, Enterococcus spp., and Klebsiella spp. were each detected with high sensitivity (68%, 78%, 87%), specificity (99%, 99%, 99%), and accuracy (90%, 94%, 98%) at a resolution of ≥10 CFU/ml within 5 h. We further demonstrate how bioluminescence in urine can be used to predict phage antibacterial activity, demonstrating the future potential of reporter phages as companion diagnostics that guide patient-phage matching prior to therapeutic phage application
A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
Aim Chemoresistance is a major cause of treatment failure in colorectal cancer (CRC) therapy. In this study, the
impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was investigated using in silico, in vitro,
and in vivo approaches.
Methods Gene expression data from a well-characterized cohort and publicly available cross-linking immunoprecipi‑
tation sequencing (CLIP-Seq) data were collected. Resistance to chemotherapeutics was assessed in patient-derived
xenografts (PDXs) and patient-derived organoids (PDOs). Functional studies were performed in 2D and 3D cell culture
models, including proliferation, spheroid growth, and mitochondrial respiration analyses.
Results We identifed IGF2BP2 as the most abundant IGF2BP in primary and metastastatic CRC, correlating with
tumor stage in patient samples and tumor growth in PDXs. IGF2BP2 expression in primary tumor tissue was signif‑
cantly associated with resistance to selumetinib, geftinib, and regorafenib in PDOs and to 5-fuorouracil and oxalipl‑
atin in PDX in vivo. IGF2BP2 knockout (KO) HCT116 cells were more susceptible to regorafenib in 2D and to oxaliplatin,
selumitinib, and nintedanib in 3D cell culture. Further, a bioinformatic analysis using CLIP data suggested stabiliza‑
tion of target transcripts in primary and metastatic tumors. Measurement of oxygen consumption rate (OCR) and
extracellular acidifcation rate (ECAR) revealed a decreased basal OCR and an increase in glycolytic ATP production
rate in IGF2BP2 KO. In addition, real-time reverse transcriptase polymerase chain reaction (qPCR) analysis confrmed
decreased expression of genes of the respiratory chain complex I, complex IV, and the outer mitochondrial membrane
in IGF2BP2 KO cells. Conclusions IGF2BP2 correlates with CRC tumor growth in vivo and promotes chemoresistance by altering mito‑
chondrial respiratory chain metabolism. As a druggable target, IGF2BP2 could be used in future CRC therapy to
overcome CRC chemoresistance
- …